12.02.2021 15:06
Dear reader
In December last year, NBE Therapeutics was acquired for more than EUR 1 billion, followed in January by the sale of Arvelle Therapeutics at a similarly high valuation. In February, the next Swiss start-up to achieve unicorn status arrived: Nexthink has completed a USD 180 million funding round on a valuation of USD 1.1. billion.
In a LinkedIn post, Nexthink CEO Pedro Bados comments that for him fundraising announcements not as interesting as the announcement of achievements, such as business growth. In fact, in the case of Nexthink, investor money is not the basis of its sales. It is precisely the other way around. The latest financing round follows a year of strong revenue growth that passed the USD 100 million annual recurring revenue (ARR) threshold.